Drug Trial Radar · NCT03387098
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Last checked: Nov 20, 2026Latest source record: May 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
4
Actual
Start
Dec 28, 2017
Primary completion
Sep 12, 2018
Study completion Jan 15, 2019
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 29, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy.
Conditions
- Pancreatic Cancer
Interventions
Aldoxorubicin HClDrug
Aldoxorubicin hydrochloride
ALT-803Biological
Recombinant human super agonist interleukin-15 (IL-15) complex
ETBX-011Biological
Ad5 \[E1-, E2b-\]-CEA
GI-4000Biological
Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
haNK for infusionBiological
NK-92 \[CD16.158V, ER IL-2\]
avelumabBiological
Recombinant human anti-PD-L1 IgG1 monoclonal antibody
bevacizumabBiological
Recombinant human anti-VEGF IgG1 monoclonal
CapecitabineDrug
5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
CyclophosphamideDrug
2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
FluorouracilDrug
5-fluoro-2,4 (1H,3H)-pyrimidinedione
LeucovorinDrug
L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
nab-PaclitaxelDrug
Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
lovazaDrug
Omega-3-acid ethyl esters
OxaliplatinDrug
cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
SBRTProcedure
Stereotactic Body Radiation Therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs), Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.Time frame: 30 days after last dose, up to 8 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chan Soon-Shiong Institute for Medicine
El Segundo, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.